NCT04091906Unknown不适用
Peripheral Blood Mononuclear Cell Donation Protocol for Tumor Immunotherapy Study of UCAR-T Cells
The First Affiliated Hospital with Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Collect blood samples
研究概览
简要总结
Peripheral blood mononuclear cell donation protocol for tumor immunotherapy study of UCAR-T cells
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female aged 18-40 years, no donation reaction in the past;
- •Weight: male ≥ 50 kg, female ≥ 45 kg, and 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2;
- •Blood pressure:
- •12.0 Kpa (90 mmHg) ≤ systolic pressure﹤18.7 Kpa (140 mmHg) 8.0 Kpa (60 mmHg) ≤ diastolic pressure﹤12.0 Kpa (90 mmHg) Pulse pressure ≥ 4.0Kpa (30mmHg); 4) Pulse: 60/min to 100/min. Athletes with high endurance ≥ 50/min, with regular rhythm; 5) Temperature: 36.3-37.2℃ (oral temperature); 6) Generally in good condition: no damage to important organs such as heart, lung, liver and kidney; no severe or uncontrolled infection; no history of severe mental disorders; 7) Clinical examination should meet the following criteria:
- •Hemoglobinometry: male ≥ 120g/L; female ≥ 110g/L. If using copper sulfate method: male ≥ 1.0520, female ≥ 1.0510
- •White blood cell (WBC) test: ≥4×109/L
- •Alanine aminotransferase (ALT) ≤40U/L (Rate method), ≤25U/L (Reitman-Frankel method)
- •Hepatitis B virus surface antigen (HBsAg) negative
- •Hepatitis C virus antibody (HCV antibody) negative
- •Human immunodeficiency virus antibody (HIV-1 and HIV-2 antibody) negative
- •Syphilis negative
- •Cytomegalovirus antibody (CMV antibody) negative
- •Epstein-Barr virus antibody (EBV antibody) negative
排除标准
- •Donors are ineligible to donate PBMC under the following circumstances:
- •Valetudinarian, with frequent dizziness, giddiness, tinnitus, hemophobia, fear of needles, faint, and Meniere's disease; 2) Sexually transmitted diseases (STDs), leprosy, AIDS, and HIV-1, HIV-2, CMV, EBV antibody positive; 3) History of liver diseases, HBsAg positive and HCV antibody positive. 1 year after the clinical cure of hepatitis A, normal ALT test results at 1 month interval for 3 consecutive times; 4) Relapsed allergic diseases, urticaria, bronchial asthma and drug allergies (Donors with simple urticaria who are not in acute attack are eligible to donate PBMC); 5) Pulmonary tuberculosis, renal tuberculosis, lymph node tuberculosis and bone tuberculosis; 6) Cardiovascular disease and history, various heart diseases, hypertension, hypotension, myocarditis and thrombophlebitis; 7) Respiratory diseases (including chronic bronchitis, emphysema, bronchiectasis and pulmonary insufficiency); 8) Digestive system diseases (e.g. severe gastric and duodenal ulcers, chronic gastroenteritis and chronic pancreatitis); 9) Urinary system diseases (e.g. acute and chronic nephritis, chronic urinary system infection, nephrotic syndrome, acute and chronic renal insufficiency, etc.); 10) Various hematological diseases (including anemia, leukemia, polycythemia vera and various hemorrhagic and coagulative diseases); 11) Endocrine diseases or metabolic disorders (e.g. hyperthyroidism, acromegaly, diabetes insipidus, diabetes mellitus, etc.); 12) Organic nervous system diseases or psychoses (e.g. encephalitis, sequelae of brain trauma, epilepsy, schizophrenia, hysteria, severe neurasthenia, etc.); 13) Parasitic diseases and endemic diseases (e.g. kala-azar, schistosomiasis, filariasis, hookworm disease, taeniasis, paragonimiasis, Keshan disease, Kaschin-Beck disease, etc.); 14) Malignancies and benign tumors affecting health; 15) History of haematological malignancies (e.g. leukaemia, lymphoma, myeloma), history of malignancies known to be associated with viraemic conditions (except for carcinoma in situ of the cervix). For other cancers, the donors should have fully recovered with no expectation of recurrence (i.e. cured) and the following conditions apply:
- •for cancers with negligible metastatic potential (e.g. basal cell carcinoma and carcinoma in situ of the cervix), the donors may be accepted immediately following successful removal and cure
- •for all other cancers, at least 5 years should have elapsed since completion of active treatment 16) Undergone resection of stomach, kidney, gallbladder, spleen, lung and other important organs; 17) Exposure to harmful substances or radioactive substances (except for clinical radiology); 18) High-risk groups susceptible to HIV infection, such as drug users, homosexuals and people with multiple sexual partners; 19) Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt disease (vCJD), family history, and treatment with human and animal pituitary-derived substances (e.g. growth hormone, gonadotropin, thyrotropin, etc.). Organ transplantation recipients (including cornea, bone marrow, dura mater) may be exposed to bovine spongiform encephalopathy (BSE) and vCJD; 20) Chronic skin diseases, especially infectious, allergic and inflammatory systemic skin diseases (e.g. favus, generalized eczema, systemic psoriasis, etc.); 21) Autoimmune diseases and collagenosis (e.g. systemic lupus erythematosus, dermatomyositis, scleroderma, etc.); 22) Bitten by animals carrying rabies virus; 23) Other diseases or conditions in which donors are ineligible to donate PBMC in the opinion of physicians;
- •Donors should be deferred for the time being under the following circumstances:
- •Tooth extraction or other minor surgery within half a month;
- •3 days before or after menstruation, menstrual disorders, pregnancy, less than 6 months after abortion, less than 1 year after delivery and lactation;
- •Less than 1 week after the recovery of cold and acute gastroenteritis, less than 1 month after the cure of acute urinary system infection, and less than half a year after the cure of pneumonia;
- •Donors from high-risk areas of infectious diseases as prescribed by certain infectious diseases and epidemic prevention departments. Less than half a year after the cure of dysentery, less than 1 year after the cure of typhoid fever and brucellosis, history of malaria within 3 years;
- •Within 2 years after blood transfusion treatment;
- •Less than 1 year after tattoo, injuries or contaminated wounds caused by equipment contaminated by blood or tissue fluid;
- •Close contact history with patients with infectious diseases: within the longest incubation period of the disease after the date of contact;
- •Recipients of animal serum products: within 4 weeks after the last injection;
- •Recipients of hepatitis B immunoglobulin (HBIG) injection: within 1 year;
- •Provisions for PBMC collection after immunization:
- •Asymptomatic donors who have recently received immunization may donate PBMC only after the following period of time: 2 weeks after the last immunization of measles, mumps, yellow fever, poliomyelitis and live attenuated hepatitis A vaccine, 4 weeks after the last immunization of live rubella vaccine and rabies vaccine;
研究组 & 干预措施
Healthy donor
Experimental
干预措施: Peripheral blood mononuclear cell apheresis (Device)
结局指标
主要结局
Collect blood samples
时间窗: Baseline
Collect blood samples (whole blood and PBMC) from healthy donors for the development and production of UCAR-T cells
次要结局
- Collect blood samples(Baseline)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy StudyPeripheral Blood Mononuclear CellNCT04448509He Huang50
已完成
1 期
Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver CirrhosisLiver CirrhosisNCT01503749Seoul National University Hospital9
Unknown
不适用
Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy ProductHealthy SubjectNCT04295096Jun Zhu172
已完成
不适用
In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and PatientsCell FunctionNCT00342485National Cancer Institute (NCI)5,000
已完成
2 期
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast CancerBreast CancerNCT00429572M.D. Anderson Cancer Center19